Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III
This study has been completed.
Study NCT00415519 Information provided by Mitsubishi Tanabe Pharma Corporation
First Received on December 22, 2006. Last Updated on April 18, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Amyotrophic Lateral Sclerosis (ALS)
Additional conditions recognized in this trial
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Sclerosis
More general conditions related to this trial
Central Nervous System Diseases
Metabolic Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neuromuscular Diseases
Pathologic Processes
Proteostasis Deficiencies
Spinal Cord Diseases
TDP-43 Proteinopathies
Interventions listed in this trial
MCI-186
Placebo of MCI-186
Additional drug interventions recognized in this trial
Free Radical Scavengers
Phenylmethylpyrazolone
More general drug interventions related to this trial
Antioxidants
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Sponsors listed in this trial
Mitsubishi Tanabe Pharma Corporation
Back to top of Main Content
